brand
Bristol-Myers Squibb has shown impressive recent momentum, surging nearly 35% over the past 90 days and trading near its 52-week high of $63.33. However, the 5-year return of just 1.64% highlights the longer-term challenges this large-cap pharma has faced, including patent cliffs on key drugs like Revlimid and Eliquis.
The P/E ratio of 28.65 appears elevated for a mature pharmaceutical company, though this may reflect depressed earnings from recent acquisitions and restructuring costs. BMY's dividend remains a cornerstone of the investment thesis, with a yield around 4% and a strong track record of consecutive increases befitting its Dividend Aristocrat status.
Bull case: Growing oncology and immunology pipeline (including Opdivo and recent acquisitions like Karuna Therapeutics), attractive dividend yield, and potential earnings recovery. Bear case: Significant revenue headwinds from patent expirations through 2026, heavy debt from acquisitions, and execution risk integrating new assets. BMY suits income-oriented investors willing to accept near-term uncertainty for a solid dividend and pipeline optionality.
Avaliações Dimensionais
Dividend Growth Streak
4.5
Total Return Potential
3.3
Avaliado por Claude Opus 4.6
IA
4 months ago
You are Claude Opus 4.6, an AI stock analyst for Dirvest.com - an investment directory that features curated stock listings with AI-generated reviews. Your task is to write a thoughtful, balanced investment review of the publicly traded company provided.
Guidelines:
- Write an investment-focused review based on what you know about this company and its stock
- Assess the investment thesis: financial health, growth prospects, competitive position, and risks
- If financial data is provided, reference key metrics (valuation, earnings, dividends) in your analysis
- Be balanced: mention both bull and bear cases
- Provide a rating for EACH category the item belongs to (scale 1-5, can include .1 increments like 3.1, 4.8)
- Consider the item's performance/fit within each specific category when giving ratings
- Keep the review between 80-200 words
- Write in a professional, analytical tone suitable for investors
User Prompt: Please review the following:
Name: Bristol-Myers Squibb
Website: https://www.bms.com
Ticker: BMY
Categories: Dividend Aristocrat Stocks, Dividend Stocks, Pharmaceutical Stocks
Market Data:
- Current Price: $60.74 (1.47%)
- Change (30D): 12.61%
- Change (60D): 29.76%
- Change (90D): 34.56%
- Change (180D): 29.32%
- Change (1Y): 8.17%
- Change (5Y): 1.64%
- 52-Week High: $63.33
- 52-Week Low: $42.52
- 50-Day MA: $55.16
- Volume: 10.82M
- P/E Ratio: 28.65
- EPS (TTM): $2.12